Beryl Drugs share price
BSE: 524606Pharmaceuticals & BiotechnologySmall Cap
Beryl Drugs Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 1994
Last close ₹23.75down ₹1.12 (4.50%)
Share price at the BSE close on 27 Oct 2026. Previous close ₹24.87.
27 Oct: open ₹25.37, high ₹25.37, low ₹23.75
52-week range of traded prices to 27 Oct 2026
₹15.92Low, 4 Mar 2026₹27.90High, 21 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹12 Cr4,587th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 19.29
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.22
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 6.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 223
Results
Standalone; ₹ crore.Beryl Drugs quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +8.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +169.1%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹7.30 Crup 42.26%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹0.22 Crdown 60.75%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 3.0%
Revenue by quarter
Peak revenue ₹7.30 Cr, quarter to Jun 2026; lowest ₹3.78 Cr, quarter to Dec 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 1 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.61 | 5.31 | 3.97 | 4.79 | 5.12 | 3.78 | 5.13 | 7.30 |
| Net profit | 0.01 | 0.05 | 0.15 | 0.02 | 0.01 | −0.17 | 0.56 | 0.22 |
| Net margin | 0.1% | 1.0% | 3.8% | 0.4% | 0.2% | −4.4% | 11.0% | 3.0% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹19 Crdown 11.00%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹0.42 Crdown 26.62%
- Net margin
- 2.3%
Revenue by year
Peak revenue ₹27 Cr, year to Mar 2023; lowest ₹11 Cr, year to Mar 2017
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.3 | 15.2 | 13.0 | 12.8 | 14.1 | 14.6 | 26.9 | 26.7 | 21.1 | 18.8 |
| Net profit | 0.1 | 1.0 | 0.6 | 0.0 | 0.2 | −0.7 | 0.8 | 0.8 | 0.6 | 0.4 |
| Net margin | 1.0% | 6.5% | 4.6% | 0.4% | 1.7% | −4.5% | 2.8% | 2.9% | 2.7% | 2.3% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICAL COMPANY, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Beryl Drugs PE ratio and valuation
Price to earnings
At or below today's level on 36% of 919 trading days over the last 5 years.
LowestHighest
Its median27.34Industry median28.51
Price to book
At or below today's level on 71% of 1,821 trading days since Nov 2018.
LowestHighest
Its median0.86Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −8.4% | −26.6% | +24.8% | 0.0% |
| 3 years | +16.6% | −17.8% | +41.9% | 0.0% |
| 5 years | +23.9% | +12.1% | +10.5% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2021.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Beryl Drugs insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group15 purchases, 0 sales₹0.15 Cr1 more with no value filedNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.15 Crof the trades with a value
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Beryl Drugs competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 7 companies closest to Beryl Drugs in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Venmax Drugs and PharmaceuticalsVENMAX | 16 | – | – | +385.7% | – | – | – | 0.00% |
 Zenith Health CareZENITHHE | 16 | 101.10 | 2.18 | −9.3% | – | 2.2% | −1.2% | 0.00% |
| Mono PharmacareMONOPHARMA | 16 | 44.40 | 0.50 | −1.6% | −88.3% | 1.1% | – | 0.00% |
 Desh Rakshak AushdhalayaDESHRAK | 15 | 27.77 | 1.15 | −24.3% | – | 4.7% | 5.8% | 0.00% |
 Unjha FormulationsUNJHAFOR | 12 | 24.71 | 3.03 | +13.0% | +386.7% | 13.5% | 15.2% | 0.00% |
 Ortin GlobalORTINGLOBE | 10 | – | 8.38 | −58.3% | – | −56.2% | −52.2% | 0.00% |
 Dipna PharmachemDPL | 10 | – | – | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Beryl Drugs announcements
Oct 2026
7 Oct · Compliance-57 (5) : intimation after the end of quarter
Sep 2026
29 Sep · Meeting
29 Sep · Approval For Increase In The Limit Of Material Related Party Transactions With M/S. Aminova Infusions Pvt. Ltd.
29 Sep · Meeting
3 Sep · Meeting
Beryl Drugs share price by year
Each calendar year to 2025.Beryl Drugs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 23.40 | −35.3% | 37.43 | 17.48 |
| 2024 | 36.15 | +63.5% | 44.40 | 22.50 |
| 2023 | 22.11 | +70.1% | 25.50 | 11.56 |
| 2022 | 13.00 | +7.3% | 14.80 | 7.95 |
| 2021 | 12.12 | +54.0% | 18.40 | 5.18 |
| 2020 | 7.87 | +60.9% | 9.30 | 3.47 |
| 2019 | 4.89 | −46.3% | 9.55 | 3.77 |
| 2018 | 9.10 | −2.3% | 16.89 | 8.35 |
| 2017 | 9.31 | −42.0% | 16.55 | 9.31 |
| 2016 | 16.05 | −49.7% | 36.95 | 15.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 26 Oct 2026 | 24.69 | 25.00 | 23.00 | 24.87 | 24.67 | 2,726 |
| 23 Oct 2026 | 25.00 | 25.00 | 24.00 | 24.69 | – | 31 |
| 22 Oct 2026 | 26.96 | 26.96 | 22.00 | 24.89 | 23.86 | 123 |
| 21 Oct 2026 | 27.90 | 27.90 | 23.10 | 24.96 | 24.16 | 1,251 |
| 19 Oct 2026 | 24.99 | 24.99 | 23.10 | 24.84 | 24.50 | 255 |
| 16 Oct 2026 | 24.00 | 24.74 | 22.51 | 23.81 | 23.01 | 2,605 |
| 15 Oct 2026 | 23.08 | 24.97 | 23.08 | 23.37 | 23.84 | 3,864 |
| 14 Oct 2026 | 25.89 | 25.89 | 23.60 | 25.02 | 24.76 | 893 |
| 13 Oct 2026 | 23.03 | 25.29 | 23.03 | 23.51 | 24.40 | 1,572 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 524606
- ISIN
- INE415H01017
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.beryldrugs.com
- CIN
- L02423MP1993PLC007840
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1993
- Registered office
- 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore 452016, Madhya Pradesh
- Share registrar
- Adroit Corporate Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments